COMPANY

Cellphire, Inc.

HQ: Rockville, MD source · cellphire.com ↗ · Mid-Atlantic

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Thrombocytopenia Bone Marrow Aplasia Cardiac Surgery Bleeding Hematologic Malignancy Myeloproliferative Disorders Myelodysplastic Syndromes Platelet Refractoriness Hematologic Diseases Thrombosomes Human platelets Thrombosomes®

5Trials (company is sponsor)

Timeline

Oct 27, 2021 Trial start Phase 2/Phase 3: DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) source ↗
Mar 5, 2021 Trial start Phase 2: Thrombosomes® in Bleeding Thrombocytopenic Patients Study source ↗
Mar 19, 2018 Trial start Phase 1: Thrombosomes® in Bleeding Thrombocytopenic Patients source ↗
2014-09 Trial start Early phase 1: Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT04709705	DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)	Phase 2/Phase 3	Completed	Oct 27, 2021	May 8, 2025 (actual)
NCT04619108	Thrombosomes for Expanded Access Use	Not listed	No longer available	Not listed	Not listed
NCT04631211	Thrombosomes® in Bleeding Thrombocytopenic Patients Study	Phase 2	Terminated	Mar 5, 2021	Jan 7, 2022 (actual)
NCT03394755	Thrombosomes® in Bleeding Thrombocytopenic Patients	Phase 1	Completed	Mar 19, 2018	Aug 1, 2019 (actual)
NCT02223117	Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)	Early phase 1	Completed	2014-09	Jul 21, 2016 (actual)